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Abstract. This report is based on data obtained from 64 lepromatous cases. Despite 
many years of DDS monotherapy, the homogenates from biopsies of these patients revealed 
104 or more bacteria. From the beginning of combination therapy with synergistic-
acting substances (rifampicin + isoprodian (INH + PTH + DDS) the logarithms of the 
number of bacteria in the homogenates decreased, both during treatment period and during 
treatment-free observation period (Figs. 3-8). During the whole time biopsies were taken 
almost monthly. A considerable regression of the bacterial mass or even «negativity» could 
be observed within a relatively short time. Once started, the process of reduction of bacteria 
continued also after termination of therapy. To be able to evaluate a medication, therapy-
free observation periods (for a minimum of 5 years) are indispensable. 
1. General Background 
1.1 
Since about the middle of the 1930s re-
search activities in the field of antibacterial 
chemotherapy have progressed to such an 
extent that almost any infectious disease is 
amenable to treatment today. During the 
same period methods were developed 
1 This work is dedicated to Dr. S. G. Browne, 
London, on the occasion of his 70th birthday, in 
recognition of his encouragement of leprosy re-
search for many years. 
which, for any new substance, permit a 
quick decision about its value as a medica-
ment. 
1.2 
Studies in 4 main fields - (1) in vitro ex-
periments (bacterial cultures); (2) in vi,vo 
experiments (laboratory animals); (3) deter-
mination of the serum activity in humans, 
and (4) pilot studies in patients - lead to the 
following conclusions: 
(a) In in vitro experiments most che-
motherapeutic substances act bacteriostati-
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cally, while only a few induce bactericidal 
action. 
(b) Substances known up to now as bac-
tericidal in vitro do not have bactericidal ef-
fects when applied in monotherapy in hu-
mans because of the special conditions re-
garding dosage, bioavailability, and elimina-
tion. 
(c) The likelihood of obtaining an ap-
proximate bactericidal therapeutic effect 
will be higher with a combination of syner-
gistic acting substances bactericidal in vitro. 
Combinations also prevent the development 
of drug-resistant bacterial populations. 
(d) Combination therapy enables us to 
practice short-term therapy which is indis-
pensable, since bacteriostatic long-term 
therapy practiced as monotherapy, with low 
dosage and discontinuous application ex-
poses the most dangerous errors in the field 
of antibacterial chemotherapy. 
2. Application to Leprosy 
2.1 
If leprosy treatment as normally applied 
today is examined on the basis of the 
knowledge common to all chemotherapists, 
monotherapy with dapsone must be regard-
ed as outdated. 
As generally applied, it is not very effec-
tive and inevitably leads to drug resistance. 
If patients are kept under treatment for life 
as claimed for lepromatous cases, their pri-
marily chemosensitive bacteria population 
will in the end become dapsone-resistant, 
depending on the duration of treatment, and 
cannot be influenced any longer by DDS. 
The further development of leprosy 
treatment should have the aim of making a 
patient noninfectious within a short period 
of time and of enabling us to terminate the 
therapy of each individual patient by cur-
ing him. For practical reasons the medica-
tion should be applicable to outpatients, it 
should also be well tolerated and as inex-
pensive as possible. 
3. Combined Therapy 
3.1 
The objective so defined can only be 
reached with combinations [6, 16, 57, 62] of 
known or new substances which are availa-
ble and combinable. New substances cannot 
be created with a special suitability for lep-
rosy treatment. They are detected without 
exception during general chemotherapeutic 
research. Rifampicin is one of the latest ex-
amples. 
3.2 
The following methods may be used in 
order to spot among the antimycobacterial 
substances available at present those from 
which a therapeutic anti-leprosy effect can 
be expected: 
(a) Determination of their in vitro activ-
ity against as many mycobacterial strains as 
possible [45, 46], in order to find those with 
the highest effect against as many strains as 
possible. 
(b) Determination of the experimental 
anti-leprosy effect in the mouse footpad test 
[42, 52] and of the experimental therapeutic 
effectiveness demonstrated in mice (mari-
num test) [20,22,30,49]. 
(c) Determination of the 'therapeutic ac-
tivity' [19, 23-25, 47, 49] of single and 
combined substances by assessing serum ac-
tivity in humans (biological availability after 
administration of doses justifiable for thera-
Combined Therapy in Leprosy 
peutic purposes [Figs. 1, 2] with M. mari-
num and other mycobacterial species serv-
ing as test strains). 
(d) Cautious clinical application (pilot 
studies) under careful and continuous ob-
servation and registration of all accessible 
data [2, 3, 5, 10, 11, 26, 28, 32, 37, 43, 44, 
58-60]. 
3.3 
Shepard [53-55] and others [27, 29, 31] 
demonstrated in the mouse footpad test that 
substances with a broad antimycobacterial 
effect also act upon M. leprae. However, re-
sults obtained in in vitro and animal experi-
ments do not furnish any conclusion regard-
ing their therapeutic usefulness and applica-
bility to humans. The therapeutic effect of 
medicaments in leprosy has so far almost 
exclusively been determined by empirical 
administration to patients. This procedure is 
open to question even with chemotherapeu-
tic substances which can be applied without 
any restriction to a complete scale of experi-
ments. In the case of leprosy, it is absolutely 
unsuitable, partly because of organisatory 
problems, but mainly for reasons of certain 
well-known but still insurmountable me-
thodical difficulties. 
Up to now M. leprae cannot be cultivat-
ed in vitro in the required quantity, and up 
to this date we do not have a model for ani-
mal experiments completely suitable for 
therapeutic research: 
(a) The mouse footpad test [42, 52]. 
Here, the M. leprae survive and multiply 
only for a certain time, not for immunologi-
cal reasons, but because of the conditions in 
the mouse tissues which do not allow sur-
vival of the bacteria for a longer time. The 
bacteria demonstrate only a low virulence in 
these research animals. Therefore, it might 
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happen that the therapeutic efficacy of test-
ed substances will be overrated, and fol-
lowed by dosage schedules too low for ther-
apeutic action in humans. 
(b) In armadillos [35] leprosy bacteria 
seem to multiply more rapidly. These ani-
mals are, therefore, suitable as a living me-
dium for gaining larger quantities of M. le-
prae. They can, however, not yet be used as 
model in chemotherapeutic research. 
(c) The marinum model [19, 30, 49]. 
This is based upon the fact that M. mari-
num belongs to those strains which are little 
sensitive to antimycobacterial substances 
normally used, and whose inhibition, there-
fore, requires a high antimycobacterial ac-
tion. M. marinum permits almost unlimited 
application in in vitro experiments. 
M. marinum is also virulent in mice so that 
therapeutic experiments can be carried out. 
M. marinum is a useful substitute for the 
nonavailable M. leprae in the evaluation of 
activity and synergism inherent in anti-le-
prosy drugs by determination of the serum 
activity in humans (genetic or immunologi-
cal relationship between M. marinum and 
M. leprae are irrelevant in chemotherapeu-
tic research). 
However, also the marinum model is 
only an indirect one. Like the mouse foot-
pad model it is a compromise, of interest 
only as long as no direct model (by means 
of cultivation of M. leprae and finding of in-
fectable research animals) will be available. 
(d) Theoretically, hairless mice should 
have little cellular immunological potency 
because of their extremely reduced thymo-
lymphatic apparatus [15,40,50,51]. There-
fore, they should be ideal animals for ex-
periments in leprosy research. The few ex-
periments conducted so far have given con-
flicting results [1, 8, 38, 41], but sup-
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port our theory, derived from the results of 
our own experiments that the common hy-
pothesis of leprosy immunology is not in ac-
cordance with reality. These experiments 
did not provide any results which should be 
considered with regard to chemotherapy. 
3.4 
Therapists are confronted with at least 
equally important difficulties in the evalua-
tion of the therapeutic effect: 
(a) Shrinking or disappearance of lepro-
mas, improvement of sensorial, motorial, 
and immunological symptoms, and the pa-
tient's general well-being are, of course, im-
portant impressions to the physician and his 
patient. These impressions, although diffi-
cult to determine scientifically, have to be 
included in the final judgement of all cases. 
(b) The comparison of bacteriological re-
sults offering more objective criteria of 
judgement, is, however, only applicable to 
bacteriologically positive cases and is based 
upon findings which are also posing prob-
lems - the shape and number of bacteria: 
The shape of bacteria. Mycobacteria 
show an extraordinary variability in shape, 
depending on the environmental conditions 
[4, 36]. The still wide-spread opinion that 
only solid forms are to be considered viable 
bacteria can no longer be supported [12, 
14]. Information about the effect of anti-le-
prosy substances based solely upon the in-
fluence on the morphological index (MI) 
within the first months of treatment have 
only little scientific value. Gradual rarefac-
tion of bacteria, appearance of granulations, 
and their decomposition into particles are 
nevertheless and undoubtedly products of 
an effective therapy, but up to this date it is 
unknown which parts of tlle total acid-fast 
material are not viable. 
The number of bacteria. Great impor-
tance should be attributed to the decline and 
with that to the reduction of the number of 
bacteria including the shrinkage of the total 
acid-fast material. The demonstrable quality 
depends on the preparation technique as 
well as on the staining methods. A distinct 
reduction of bacteria is nevertheless recog-
nizable and its degree measurable to a cer-
tain extent. In the ideal case the number of 
bacteria is reduced to zero [48]. Up to now, 
however, there is no practical experience as 
to how often and in which intervals a reduc-
tion to zero should be demonstrated and in 
which material, until a patient can be con-
sidered 'negative' and what therapeutic con-
sequences (discontinuation of therapy for 
instance) may be considered. 
4. Relapse Control 
Clinical evidence of definite improve-
ment and reduction of the bacterial mass 
are, despite all reservations, criteria for a 
judgement of a therapeutic performance 
during treatment. A final decision regarding 
the total therapeutic value of a medication 
can, however, only be made by relapse con-
trol after discontinuation of treatment. 
There should be an observation period 
(therapy-free) of at least 5 years after termi-
nation of treatment, which could only be 
justified by selection of patients willing to 
cooperate and with continuous collabora-
tion of qualified physicians. One has to 
free oneself from the dogma of a lifelong 
treatment called for in lepromatous cases, 
and to terminate therapy in accordance with 
justified criteria. Evaluation of medication in 
leprosy treatment without relapse control is 
incomplete and may cause grave errors. In 
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consideration of this point of view, none of 
the investigations with combined therapy 
carried out since 1960 complies with the 
conditions to be met in a correct trial. 
This does not mean, however, that the 
publications lose their value. They furnish im-
portant partial information and demonstrate 
clearly, apart from other facts, that control-
led studies are not practicable in leprosy. 
5. Our Own Results 
5.1 
On the basis of experimental [19,22, 23, 
47, 49] and clinical investigations [2, 3, 5, 
10, 11, 28, 32, 37, 43, 44, 58-60] we prefer 
four substances (a-d) for combined therapy 
[17, 18] whose pharmacokinetic properties, 
bioavailability, compatibility, and antibac-
terial activity against M. leprae are general-
ly known (figs. 1, 2): 
(a) Rifampicin (RMP) administered in 
the dose of 10 mg/kg/day. Its efficiency is 
excellent in the mouse footpad and marin-
urn test. It is also clinically effective and is 
well tolerated. 
(b) Isoniazid (INH) administered in the 
dose of 5 mg/kg/day shows an anti-leprosy 
activity in experimental [54] and clinical [7, 
9, 34] use and also serves as a valuable syn-
ergistic component in drug combinations. 
Another advantage of isoniazid is its well-
proved action against M. tuberculosis. It is 
therefore possible to compose universally ap-
plicable antimycobacterial medications (19). 
(c) Prothionamide (PTH) administered 
in the dose of 5 mg/kg/day. The dose of 
15 mg/kg used up to now was not well toler-
ated by most patients, which made thera-
pists almost completely withdraw PTH from 
tuberculosis treatment. In combined therapy 
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(also for tuberculosis) only 5 mg/kg are re-
quired, which the patients tolerate without 
difficulty, so that the action of this sub-
stance can be utilized. It is highly effective 
in the mouse footpad and marinum test. 
(d) Dapsone (DDS) administered in the 
dose of 1-2 mg/kg/day. It is very well toler-
ated, has a reliable effect in the mouse foot-
pad and marinum test, and is of undoubted 
clinical efficacy. Used in combined therapy, 
it produces an excellent synergistic action 
which has not yet been explained in all de-
tails. The often repeated assertion that dap-
sone induces leprosy reactions when admin-
istered in an effective dosage in leprosy 
treatment, could not be confirmed by us or 
by other physicians [61]. 
(e) Clofazimine (Lamprene, B 663) is 
highly appreciated by many leprologists, al-
though many years ago, when its introduc-
tion into tuberculosis treatment was dis-
cussed, we had already decided against its 
application because of its toxic properties 
[21]. In leprosy we could in certain in-
stances convince ourselves of its low efficien-
cy and its toxicological disadvantages. The 
statements of Jopling [33], Desikan et al. 
[13], Mason et al. [39], and others confirm 
our own experience. The discoloration of 
the skin caused by this substance might be 
tolerated in the case of excellent therapeutic 
results, but it is extremely disturbing be-
cause of accumulation in the lepromas, pre-
senting them often very conspicuously. It 
may take years before the color of the skin 
returns to normal. Up to now the immuno-
depressive effect of clofazimine has not 
been proven, but even if it existed, in itself 
it would not be an indication for its applica-
tion without any other backing. Preference 
should rather be given to thalidomide [56] 
because of its reliable effect, better toler-
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1 - - - +1\111 + 1\l!! *l!! 111111lH M.ulcerans 3 + ltI M.marinum - - - M. fortuitum +11 111111 tliltl 
10022 5 111 SN 1301 +111 SN 203 + III lttltt tIi\\l* 
7 -
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Fig. 1. Simultaneous determination of serum 
activity (human test persons) after intake of rif-
ampicin + isoprodian in therapeutic doses. Parallel 
inoculation of 12 mycobacterial strains (M. intra-
cellulare, M. marinum, and M. avium with two 
strains each to demonstrate the different sensitivity 
of strains of the same species). h = time of with-
ance and lower price (except for women 
likely to conceive). 
(f) Sulfonamides, especially long-acting 
sulfonamides, are effective, but may cause 
serious allergic reactions if administered 
over a long period of time. They must be 
taken daily in relatively large doses. There-
fore, they are not suitable for application in 
mono therapy and, compared with dapsone, 
they are rather disadvantageous in com-
bined therapy. 
(g) We still lack sufficient experience in 
the application of other currently used 
substances within drug combinations, but 
III 11 1\\ ll<tIitli 
tIi ltI 
ItI 
drawal in hours after intake of drugs. Culture 
medium Lockemann (mod. Bonicke). Bacterial 
inoculation: 6 X 10-3 mg. For serum dilutions 
~ 2-5 addition of 6% bovine serum. Reading time 
when growth ( + + + ) was registered in the control 
serum (time 0). No growth (-). 
we are looking for these to be applicable in 
fixed combinations. 
5.2 
Our practical experience is mainly based 
on the combination of rifampicin + isopro-
dian [RMP + (INH + PTH + DDS)] which 
was examined in several pilot studies [2, 3, 
5, 10, 11, 28, 32, 37, 43, 58-60]. These sub-
stances can be given to outpatients and the 
three last ones (INH, PTH, DDS) integrated 
in a fixed combination called isoprodian 
(each tablet containing 175 mg of INH, 
175 mg of PTH and 50 mg of DDS, normal 
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M.marinum h Serum dilution M.marinum h Serum dilution 
SN 1254 SN 1254 
2 
alii illIIl!! 01«1« 1«\11 
1 * It\1\I1\\ 1 - lIHI! 
31\1 Il\llll\! INH 5 mg/kg 3-1+ l\!\II 
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gill lllllllll 9 *1\\\11 
24 ill illW1\\ 24 \11\11 tlIltI 
all! \111\Illl 0111 ltIitlltI 
1 Hf1\\ 1 +* ItIItI 
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00S-1.5mg/kg g+ +*\11 RMP 10mg/kg 5-- *\11 
7{+) 1flll1\\ 7 HHIl 
g +) +llllll 9 tt !IIlH 
24 ffi lllllllll 24 III 1\\ltItlI 
Oltl lti\\HtI 01\\ llIllltil 
1 - --It lHm RMP 10 mg/kg 1 - -- -+ ll11it 
3 +\f tlI1Jt PTH 5 mg/kg 3-- - 1\1l! 
PTH 5mg/kg S-fl lItlH 1Jt1\\ INH Smg/kg 5- - - -+ It III 
7 lit lll1\\ llll\! 00S-1.5mg/kg 7 - - -# lHlll 
gilt 1lIti1 III \11 9 \f\ll 1\\l1I 
24 ItI l\!\IIllI 24 lH lH\II\II 
Fig. 2. Determination of serum activity (human 
test persons) after intake of INH, DDS, PTH, 
RMP, INH + PTH + DDS and RMP+ PTH + INH + 
DDS. Symbols and methods as in Fig. 1. 
daily dose 2 tablets for adults). This facili-
tates considerably the treatment of outpa-
tients and renders intake more certain. The 
patient's active collaboration is thus much 
more easily obtained. Fixed combinations 
also facilitate the control of regular intake, 
since only one component of the combina-
tion has to be tested in urine. 
5.3 
This report is based upon results ob-
tained with cases of our leprosy eradication 
project in Malta because they belong to 
those which were thoroughly examined. 
Among the patients with whom we started 
the first part of the project [24] in June 
1972 there are 64 lepromatous cases (bac-
teriologically positive results confirmed by 
histological slides, smears and homogenates) 
which are especially interesting. These cases 
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revealed a minimum of 104 bacteria in the 
homogenate at the outset of our project, al-
though most of them had been pretreated 
with dapsone in monotherapy during a long 
period of time. 
5.4 
The data of these cases forming the sub-
ject of this report are gathered in groups in 
figures 3-8 and are explained there in de-
tail. To avoid repetitions, please see the text 
of the figures in which all essential informa-
tion is given. 
6. 
The evaluation of the therapeutic effect 
here refers to the number of bacteria in the 
homogenate. It can be quantified in the best 
way and is indispensable for scientific pur-
poses. Smears made in parallel give compa-
rable results. However, they may still con-
tain acid-fast material which is no longer 
detectable in the homogenate because of the 
dilution technique. Smears are sufficient for 
controlling the therapy effect in practice. 
7. 
Therapy was discontinued on the basis 
of a compromise achieved under bacterio-
logical, clinical, sociological, and even psy-
chological aspects, which have to be consid-
ered in Malta just as in almost all other 
countries as well as in case of any other dis-
ease if an eradication project has to be es-
tablished. It goes without saying that the 
clinical-bacteriological aspect was always 
preponderant. In retrospect we seem to 
have treated many cases for a longer period 
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ICOMBINED THERAPY WITH RMP + ISOPRODIAN UNH+ PTH+ DOSII 
Treatment period in months 
Therapy 
discontinued Control period without treatment in months <.orial Case DOS START ~. Name . ---+ L.8 
No. No, since 36 24 12 12 24 36 48 
1 T. D. 16449 1966 3442 3 4 2 322 33 2 
2 D.G. 0392 1959 T 42 
3 M.M. 2204 1968 T3 342 
4 S.A. 58053 6· 3 
5 B.L. 14457 1965 T 
6 B.R. 29665 34 22·2221 2-2 
7 M.S. 18469 1968 
8 P.R. 15451 1965 
9 C.D. 14390 1965 
10 M.M. 04588 1959 
T4 
T 
T 
Fig. 3. 10 cases. Treatment discontinued when 
the homogenate no longer revealed acid-fast mate-
rial. Cases continued to be negative during the 
control period without treatment. Observation 
of time than absolutely necessary. We were 
led to this conclusion by those patients who 
had become and also remained negative 
(Fig. 3) long before termination of treat-
ment, but also by other cases where we had 
to take the risk of an early discontinuation 
of therapy for additional reasons and in 
whom the healing process was not at all dis-
appointing (Figs. 4, 5). 
8. 
During therapy-free observation period 
there may occasionally occur residues of 
acid-fast material. In case of clinical im-
provement therapy was not resumed, be-
cause of careful continuous relapse control. 
Occasional fluctuations of bacteria in homo-
genates have to be explained methodically 
by counting also bacterial residues which 
are surely not viable bacteria. If patients are 
controlled monthly over a long period of 
time it is not reasonable to take several 
biopsies at a time. This method would not 
55 31 
3332 
4·3 
without treatment is continued. Bacteria were 
counted in the homogenate. Each single number 
represents the logarithm of the counted bacteria. 
• = No bacteria revealed; T = outset of therapy. 
offer a complete guarantee against nonuni-
formity of each single result, and it becomes 
doubtful as soon as an average value will be 
calculated. Nor can it be recommended to 
take biopsies always from the same lepro-
ma. The withdrawal itself creates a new lo-
cal situation rendering difficult the compari-
son with previous results. If a biopsy is tak-
en monthly it should always be chosen from 
different places. The greater safety ac-
complished can then be attributed to the re-
sults remaining constant over a long period 
of time. One single positive result revealing 
a great number of bacteria is always impor-
tant, one single negative result means hardly 
anything. Only the continuous regression of 
the bacteria is significant (48). 
If after 12 months of treatment no evi-
dent diminution of the bacterial mass can be 
registered in a patient, one can be sure that 
the medicaments were either refused or tak-
en irregularly. Hospitalization may then be 
successful. There may also exist cases not 
responding to therapy - a phenomenon 
which would have to be investigated. 
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ICOMBINEO THERAPY WITH RMP • ISOPRODIAN ilNH • PTH • DDS)i 
Therapy 
~rial Case DOS START Treatment period in months discontinued Control period without treatment in months Name 
-----+ 48 36 24 12 12 24 36 No. No. ince 48 
1 T.S. 18135 1958 S 45555 43 55 44 445453343' 1'2-22' 2 -2~--
2 A.P. 10933 1955 444343 ·3 43·332·44·322 2-2 122 
3 M.G. SB052 1950 445543333 33 33333' 222 -3'21-2 
4 G.C. 21013 1969 2443533·2 - 2·2 2 3-22 
5 G.P. 26313 1972 T4 3'2 2 22 2 
6 R.A. 01863 1955 T4 33234 12 333 -3 1-----331 2-2 
7 M.B. 20915 1962 T 42 2 ·22 1-2.2-222- 2·2---2--
8 C.R. SB038 1963 5554345353434 3223 43 2'2222·2 2-2 
9 M.M. SB036 1955 T 3 .4 3 2 
10 C.T. 3860 1971 T44 ·33- 2 2 
11 C.C. 50054 1950 T3 3 4 22 2 1 
12 B.G. SB04] 1949 T54 44 43.432·2 2 
- 23 22 2 
13 Z.S. SBOO8 1946 T 4 434.4·2 2-2 22-2 
14 S.C. ~B031 1949 T 2 34 2 22 2 2 
15 A.M. 4940 1965 , 2 2 
16 C.A. 19223 1968 T 3 .4.42· 12 2 
17 F.J. 58041 1965 5 33413 22- I 22 
18 B.R. 8241 1961 T4 2 2223 2 2 2 
19 M.W. 05382 1946 T4 34 2 
20 A.G. 07085 1961 4 32 2 2 2 
21 G.C. 22326 1971 T 4 33 
22 S.T. 01379 1955 T4 ·2 2 ·2 3 
23 e.G. 26235 1950 4543. 33· 43 2- 2- 2·2 1-1 
Fig. 4. 23 cases. Treatment discontinued. Dur-
ing the control period without treatment minimal 
debris of acid-fast material was again revealed. 
Rapid fluctuation towards 'negativity'. Control 
without treatment is continued. Symbols as in fig-
ure 3. 
erial Case DOS START 
Name 
--
48 No. No. since 
1 S.L. 12440 1964 T 5 
2 S.C. 50037 1962 4 
3 S.F. 22702 1970 T4 
4 Z.M. 2728S 
5 B.J. SBOO9 1953 
6 G.C. 50035 1948 
7 C.P. 19550 1968 
ICOMBINED THERAPY WITH RMP'ISOPRODIAN IINH' PTH' DDS)i 
Therapy 
Treatment period in months discontinued 
36 24 12 
535 5445 243 2343243·412-233·3· '3 
434.4- 2 2 -222·21222 ·2-2-22·2 
3 30403 4 222232313 1-2·1 
T 4 4 '2'22223'3'2'2 12 
T564 4344354 235324241·23·231 2 
Control period without treatment i n months 
36 12 24 
2 22-
2· 
2 -
2 
1332 2-2-
3434443324433 4 3 ·3·3222·222 .21222 42-2~2'22'223 ·2 
T 32 -4 2 21-2-22 22-2-2· 
Fig. 5. 7 cases. Treatment discontinued. Dur-
ing control period without treatment (more than 1 
year) bacterial debris was still revealed. Fluctua-
tion to O. Symbols as in figure 3. 
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Serial Name Case ~DS START 
--
60 No. No. Since 
1 B.J. 20660 1969 4 
2 C.P. 16532 1956 
3 Z.M. 26159 1950 
4 B.P. 14332 1965 
5 P.C. 28117 
6 A.M. 2926E 
7 F.R. 31310 
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ICOMBINEO THERAPY WITH RMP+ISOPRODIAN UNH+PTH+DDS11 
Therapy 
Treatment period in months discontinued 
46 36 24 12 
- 3232 23·2·2-22'3 2 
T64 6 5 56 65 55 4 45546654652 343443333 232-3 -3·3· 
66 5556556 676665455656665565445455 5445443 3 34 33233 
445543 52445 45 23332 ·2444323-3'2'32' 2 
T5·44·53222·1·2-22 2 
T545444 33·233·3·2 
T44·4·4~-2-2 !--
Control period with out 
s treatment in month 
12 2 4 
-
Fig. 6. 7 cases. Therapy discontinued. During 
the control period without treatment (less than 1 
year) bacterial debris was still revealed in cases 2, 
3, and 4. Symbols as in figure 3. 
ICOMBINED THERAPY WITH RMP + ISOPRODIAN UNH+ PTH + DDSlj 
Serial Case DOS START Treatment period in months Name ---+ 1 12 24 36 46 No. No. since 60 
1 A.S. 220IX 1970 T555 45445265 5 4 4323535566424233222232·522-2233334·23· 
2 M.T. 25421 1972 T6454 5455555 5 5 45435244 4344 ·33·2533242422-2232323-2 
3 S.C. 25606 1972 T64555554666 5 5 324323 53432232221354-32~~3--
4 G.F. 26191 1950 T6 74 65665 55 35455 355544333333354 332322-33222232 
5 B.F. 5805E 1952 54 4433544 4 3333 4344442422322 3423332-2·32232 332· 
6 Z.M. 26724 1950 65434435452333443222332·2·21·2 23· 
7 Z.P. 26866 T55665 5 54 332334333333221343 3232~-3·4·2232· 
6 B.M. 27223 66425555555 2325353·322 ·23·4533· 323--232-32-
9 M.M. 27669 666545 24 4545554 43 3-3423 22 ·2 2 
10 P.A. 28437 T 32443333· 3334332223222 32 
11 G. J. 00061 6633255333433 
12 X.C. 00270 6443343435243 
Fig.7. 12 cases still under treatment. Consid-
erable reduction of bacterial mass. In most cases 
discontinuation of treatment is imminent. Symbols 
as in figure 3. 
9. 
For most of the cases mentioned in fig-
ures 3-6 and 8 the following three succes-
sive (chronological) periods can clearly be 
differentiated: 
Monotherapy with dapsone did not in-
duce 'negativity' in one single case. 
Combined therapy (following immediate-
ly) led within a relatively short period of 
time to a considerable regression of the 
number of bacteria and even to 'negativity' 
already during treatment or right after its 
termination. 
Observation period for relapse control 
after termination of therapy. Since the end 
of the 5-year observation period has not yet 
been reached, no final judgement can be 
made at the present time. However, the ini-
tial results referring to control periods with-
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ICOMBINEO THERAPY WITH RMP + ISOPRODIAN !lNH + PTH + DDS)I 
Therapy Control period without 
Serial Case DOS START Treatment period in months discontinued treatment in months Name ----+ 36 24 12 12 24 3 No. No. since 6 
1 R. J. 01864 1958 T 5455333244 43322423·23 2243222~23 .j.2·2~222· 
2 A.P. 29260 55-3.3.23·123 
.j. 
4545436324 45 3344 354i244232322443 24242~2'3-223'2' 
Serial Name Case DOS START Treatment period in months 
-
1 12 24 36 48 No. No. si nce 60 
4 M.C. 58061 1960 6 65555 754 5 455 5 33433 34 334 244·2 4 656 
5 F.F. 24174 1969 543345534322 4 3 ·5223445666656·54454644533 6 
Fig. 8. No. 1 and 2: therapy discontinued. 
Continuous bacterial regression. Therapy resumed 
due to reappearance of one (No. 1) resp. several 
(No. 2) lepromas. No. 3: discontinuation of thera-
py despite high number of bacteria. Regression of 
out treatment up to 40 months are encour-
aging. 
Up to now therapy was resumed only in 
2 cases, due to the reappearance of one or 
several lepromas (Fig. 8), despite contin-
uous bacterial regression. It appears to be 
doubtful that a resumption of therapy was 
really necessary and that this phenomenon 
should actually be called 'relapse'. In lepro-
sy research we still lack a generally accepta-
ble definition of this term. 
10. Classification 
The cases discussed here were classified 
as LL cases during their initial examination 
in Malta, some of them a long time ago. No 
attention is drawn to this, because antimy-
cobacterial action does not depend upon the 
type of leprosy from which a patient is suf-
the bacterial number nevertheless continued. 
No. 4 and 5: no lasting therapeutic result due to 
sporadic intake of the medicaments. Symbols as in 
figure 3. 
fering. Such classification from the clinical-
immunological-histological point of view is 
important for diagnosis (and in the case of 
untreated patients perhaps also for progno-
sis), but not for chemotherapy. As for other 
infectious diseases, differences from nearly 
bacteria-free material to multibacterial stages 
influence merely the duration of treatment. 
11. Immunology 
In leprosy one should not rely on curing 
due to cellular-immunological defence mech-
anisms (in TT cases for instance). The fear 
that chemotherapy of lepromatous cases may 
not be permanently successful because of 
their defect in the immunological defence 
mechanisms is principally unfounded. The 
immunology of leprosy is a fascinating field 
of research. Up to the present time, however, 
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immunological methods cannot contribute 
anything to the diagnosis, therapy, prophy-
laxis, and prognosis of this disease. 
12. Conclusions 
(1) In our experience there can be no 
doubt that combined therapy is superior to 
mono therapy with dapsone. 
(2) Good therapeutic results can also be 
obtained when combinations of medica-
ments are administered to outpatients. For 
this purpose only substances with little and 
reversible toxicological effects can be used. 
(3) Patients can only be expected to take 
their medicaments regularly during short-
term therapy. 
(4) 'Negativity' can be obtained in lepro-
matous cases - even those with a high bac-
terial index (BI) - with rifampicin + isopro-
dian (INH + PTH + DDS) within 24 months 
under the most favorable conditions. 
(5) Continuous diminution of the bac-
terial mass and rarefaction of the bacteria 
up to their total decomposition are of sig-
nificance for therapeutic control. The mor-
phological index (MI) on its own is not a 
sufficient criterion. 
(6) The duration of treatment must be 
decided for each individual case in depend-
ence upon the bacteriological and clinical 
results. Apart from that, additional argu-
ments (sociological and psychological) may 
occasionally be taken into consideration. 
There is no uniform duration of treatment 
for all patients. 
(7) Once started, the process of reduc-
tion of the bacterial mass continues after 
termination of therapy provided the medica-
tion initially applied was highly effective. 
(8) If the BI remains constant over more 
than 12 months, this is practically always 
due to irregular intake of the medication. 
(9) The use of highly effective combined 
therapy drastically reduces the duration of 
treatment. An average treatment of 2 years, 
or 3 or even 4 years in special cases, is 
cheaper - even with expensive medications, 
than a lifelong therapy practiced with less 
effective medications. 
(10) We share the opinion of Browne [6] 
that monotherapy has become questionable 
now that the importance of drug resistance 
has finally been recognized. We shall be 
obliged in future to practice combined ther-
apy in leprosy. This, however, compels us 
to reconsider the methods of leprosy con-
trol. 
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